This efficacy seemed better than that in gastric cancer patients, in which the earlier study reported that positive clinical responses were obtained in 60 and 81% when treated with OK-432 alone and with OK-423 plus IL-2, respectively (Yamaguchi et al, 1995). This evidence concerns the gene IL2 and gastric cancer.